TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11112891
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol combination (FP/Salm Combo) - FP 100 microg plus salmeterol 50 microg twice daily through the Diskus inhaler
Study: 11112891
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate plus montelukast (FP + montelukast) - FP 100 microg twice daily plus oral montelukast 10 mg once daily
Study: 8840374
Drug: Erythromycin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (mean rate 8.9 +/- 3.5 mg/minute, range 3.9-16.7 mg/minute)
Study: 8840374
Drug: Control antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control antibiotics (ceftazidime, cefuroxime, cefotaxime, ceftriaxone, or ampicillin-sulbactam)
Study: 1334524
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA), 10 mg daily with conjugated equine oestrogens 0.625 mg (CEE)
Study: 1334524
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA), 10 mg daily with transdermal 17 beta‐oestradiol 0.05 mg (E2‐TTS)
Study: 6427533
Drug: Single-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose therapy with trimethoprim-sulfamethoxazole (TMP-SMZ)
Study: 6427533
Drug: 10-day multiple-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day multiple-dose therapy with trimethoprim-sulfamethoxazole (TMP-SMZ)
Study: 6427533
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (single-dose and multiple-dose)
Study: 28072691
Drug: Clopidogrel 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 50 mg plus aspirin 100 mg
Study: 28072691
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg plus aspirin 100 mg
Study: 21749907
Drug: Sertraline (N=14)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (N=14)
Study: 21749907
Drug: Escitalopram and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram and Sertraline (combined)
Study: 3071588
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg three times a day)
Study: 29890864
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg/kg) as part of a multimodal cocktail injection
Study: 29890864
Drug: Multimodal cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal cocktail injection without morphine (control group)
Study: 29231438
Drug: Needle-knife treatment
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-knife treatment (Fengchi GB 20, infraoccipital ashi point), once every three days for 5 times as one course.
Study: 29231438
Drug: Massage treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage treatment, once every two days for 7 times as one course.
Study: 19678713
Drug: Alitretinoin 10
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin 10 mg/day
Study: 19678713
Drug: Alitretinoin 30
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin 30 mg/day
Study: 15309453
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose soy protein product with added beta-sitosterol (10 g once daily)
Study: 10831195
Drug: bupivacaine-morphine (BM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine-morphine (BM)
Study: 15662995
Drug: Albendazole 800
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 800 mg
Study: 8465408
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg for 3 days
Study: 8465408
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg for 5 days
Study: 22956826
Drug: Transcranial magnetic
Normalized name: transcranial magnetic stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial magnetic stimulation (TMS) delivered simultaneously with targets of varying contrast, with a single TMS pulse; specific dosage and duration not mentioned.
Study: 17629631
Drug: tiagabine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiagabine (20 mg/day)
Study: 16269957
Drug: Low-dose felodipine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose felodipine (extended release)
Study: 12505245
Drug: Pill counts
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pill counts as a gold standard
Study: 8700313
Drug: Postoperative flomoxef
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative flomoxef administration with saline containing no antibiotics for irrigation (Group A)
Study: 2012420
Drug: 7.2% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.2% NaCl solution prepared in hydroxyethylstarch (HES) solution (HS‐HES group)
Study: 2012420
Drug: 6% HES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% HES 200/0.5 solution (HES group)
Study: 7026094
Drug: Transfer factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer factor (TF) given for 3 months at weekly intervals
Study: 26166613
Drug: Clinical score
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical score based treatment (control group)
Study: 24624781
Drug: Chemoradiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy with fractionated dose (1 Gy + 1.5 Gy or 1 Gy + 2 Gy with 4‐hour intervals to a focal dose of 60 Gy)
Study: 16931658
Drug: Bivalirudin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (0.75 mg/kg bolus followed by 1.75 mg x kg(‐1) x h(‐1) continuous infusion)
Study: 16931658
Drug: Heparin-protamine
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-protamine
Study: 7621842
Drug: Clonidine 0.1
Normalized name: clonidine 0.17 MG
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 0.1 mg (maximum cumulative dose 0.3 mg)
Study: 2229490
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin (retinoic acid)
Study: 798468
Drug: Pimozide administered
Normalized name: Pimozide
DrugBank: Pimozide (DB01100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimozide administered in a single daily dose
Study: 798468
Drug: Chlordiazepoxide administered
Normalized name: Chlordiazepoxide
DrugBank: Chlordiazepoxide (DB00475)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlordiazepoxide administered in divided daily doses
Study: 6454632
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no secretory inhibitors)
Study: 22595385
Drug: Positive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive fluid balance (PosFB) group (median 849 ml, IQR 328 - 1,552 ml, n = 19)
Study: 22595385
Drug: Negative fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative fluid balance (NegFB) group (median -1,221 ml, IQR -1,974 to -653 ml, n = 71)
Study: 17715208
Drug: Cortisol 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol 20 mg orally twice daily for 7 days
Study: 15494456
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg recombinant human TSH (rhTSH)
Study: 29200411
Drug: Polyene phosphatidylcholine
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyene phosphatidylcholine 456 mg three times daily
Study: 21730925
Drug: Intrathecal atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal atropine 100 µg
Study: 21730925
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine 100 µg
Study: 19998580
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (70 mg alendronate sodium)
Study: 19998580
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (70 mg alendronate sodium)
Study: 17518171
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion by elastomeric pump of the same analgesic solution (metamizole and tramadol)
Study: 15595587
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg kg(‐1) suxamethonium
Study: 15595587
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg kg(‐1) rocuronium after suxamethonium
Study: 12490125
Drug: Intramuscularly administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscularly administered polysaccharide nucleic acid fraction of Bacillus Calmette Guerin (PSN-BCG)
Study: 12490125
Drug: Anti-tuberculous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tuberculous therapy and thoracentesis
Study: 7806600
Drug: Indocid capsules
Normalized name: Indocid
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indocid capsules 'A' (75 mg)
Study: 7806600
Drug: Indogesic tablets
Normalized name: influenza A virus A/Indonesia/05/2005 (H5N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indogesic tablets 'B' (75 mg)
Study: 989399
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg tybamate
Study: 989399
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg secobarbital
Study: 30482218
Drug: Automated Self-Administered
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated Self-Administered 24-Hour Recalls for Children (ASA24-Kids)
Study: 28663382
Drug: Sodium nitrate
Normalized name: Sodium Nitrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium nitrate (NaNO3) ingestion (9.3 mg/kg body weight)
Study: 28663382
Drug: Placebo (NaCl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl, 8.8 mg/kg body weight)
Study: 25625260
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (starting at 300 µg kg·min) with oxygen via nasal cannula
Study: 23506279
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (soft tissue massage for 60 seconds)
Study: 23506279
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (crowns of the mandibular premolar teeth massaged)
Study: 19046094
Drug: Antioxidants (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (2 capsules of Nature Made antioxidants 2 hours before, and 2 and 8 hours after ESWL)
Study: 19046094
Drug: Antioxidants (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (2 capsules of antioxidants at 2 and 8 hours after ESWL)
Study: 16612143
Drug: 1% ciclopiroxolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ciclopiroxolamine cream applied twice daily for 28 days
Study: 16612143
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied twice daily for 28 days
Study: 9060219
Drug: Halofantrine schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine schedule II (three doses of 500 mg)
Study: 1900485
Drug: Mesterolone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesterolone (150 mg/d)
Study: 6401379
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g L-lysine orally
Study: 31542291
Drug: Antibiotic or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic or silver shunts
Study: 29521263
Drug: Manosar® (D-mannose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manosar® (D-mannose 2 g, 24h prolonged release, associated with Proanthocyanidin (PAC) 140 mg)
Study: 29521263
Drug: PAC (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC (240 mg)
Study: 16838818
Drug: drugs only
Approvals — FDA: no, EMA: no, PMDA: no
Description: drugs only (nicotine replacement therapy patch, nasal spray, inhaler, and Zyban)
Study: 16838818
Drug: drugs and
Normalized name: Prostaglandin analogues, antiglaucoma drugs and miotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: drugs and counseling (drugs and proactive telephone counseling)
Study: 16838818
Drug: drugs if
Approvals — FDA: no, EMA: no, PMDA: no
Description: drugs if counseling (drugs conditional on enrollment in counseling)
Study: 14740589
Drug: Bilateral interpleural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral interpleural analgesia (IP) using bupivacaine 0.5% (0.8 mg/kg) and 2 mg morphine diluted to 50 ml saline for each side
Study: 14740589
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural analgesia (EP) using the same mixture diluted in 20 ml saline injected in the epidural space (L2-3)
Study: 7956274
Drug: Platelet-activating factor
Normalized name: Platelet-activating factor acetyltransferase
DrugBank: Platelet Activating Factor (DB02261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-activating factor receptor antagonist (BN 52021) 120 mg intravenously every 12 hrs for 4 days
Study: 7956274
Drug: Platelet-activating factor
Normalized name: Platelet-activating factor acetyltransferase
DrugBank: Platelet Activating Factor (DB02261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-activating factor receptor antagonist (BN 52021)
Study: 3677280
Drug: Chlorpromazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (25 mg IV)
Study: 29351097
Drug: High-rate epidural
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-rate epidural bolus (300 ml/h)
Study: 29351097
Drug: Low-rate epidural
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-rate epidural bolus (100 ml/h)
Study: 24419306
Drug: Emotional awareness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotional awareness training (EMT) in addition to standard symptom‐oriented medical treatment; included two emotion awareness training sessions and daily emotion recording over 20 months.
Study: 24419306
Drug: Standard symptom‐oriented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard symptom‐oriented medical treatment (MT group) only.
Study: 24419306
Drug: Emotional awareness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotional awareness training (EMT) in addition to standard symptom‐oriented medical treatment.
Study: 12383572
Drug: Enoximone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (0.5 to 2 mg/kg intravenously)
Study: 10420746
Drug: Ramipril (0.25-0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (0.25-0.50 mg daily for 1.5-2 months)
Study: 8976498
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine administration
Study: 1441879
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg orally approximately 100 min before anaesthesia and three times daily for the first 2 postoperative days
Study: 31571712
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 500 mg/day
Study: 31571712
Drug: Propranolol SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol SR 40 mg/day
Study: 29762864
Drug: Fluticasone furoate‐umeclidinium‐vilanterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate‐umeclidinium‐vilanterol (100 μg/62.5 μg/25 μg; Ellipta inhaler)
Study: 29762864
Drug: Budesonide/formoterol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (400 μg/12 μg; Turbuhaler)
Study: 22251419
Drug: Lubiprostone 8
Normalized name: LUBIPROSTONE 8MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone 8 mcg, twice daily for 36 weeks
Study: 7494722
Drug: Structured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured treatment and teaching program for non-insulin-treated type II diabetic patients
Study: 1580072
Drug: Self-medication with
Normalized name: chloroxylenol Medicated Pad [E-Z Scrub with Ultradex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-medication with antidiarrhoeal agents, analgesics/antipyretics, antibiotics, and oral contraceptives
Study: 1580072
Drug: Self-medication with
Normalized name: chloroxylenol Medicated Pad [E-Z Scrub with Ultradex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-medication with pyrimethamine/sulfadoxine
Study: 1580072
Drug: Self-medication with
Normalized name: chloroxylenol Medicated Pad [E-Z Scrub with Ultradex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-medication with mefloquine
Study: 24498853
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg orally
Study: 20345024
Drug: Lumbar traction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar traction therapy
Study: 16236737
Drug: One year
Normalized name: Annovera 0.15 MG / 0.013 MG per 24HR One Year Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: One year of trastuzumab treatment
Study: 12198006
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg, elemental form as acetate, twice daily for 6 days)
Study: 10192202
Drug: Fecal fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal fat excretion
Study: 9278199
Drug: Trandolapril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (2 mg once daily)
Study: 2127690
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy (CAF followed by PH)
Study: 2127690
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy (CAF/PH)
Study: 27754808
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg) daily for 1 to 6 menstrual cycles
Study: 23398222
Drug: Psychosocial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial treatment in addition to treatment-as-usual
Study: 21117970
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus Fenofibrate 160 mg
Study: 8483989
Drug: Gliclazide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (40 mg twice daily)
Study: 3318433
Drug: Nabumetone 1,000
Normalized name: nabumetone 1,000 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone 1,000 mg at bedtime
Study: 3318424
Drug: Naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 250 mg twice daily
Study: 16316811
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg two to three times per day)
Study: 12904324
Drug: n‐3 polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 polyunsaturated fatty acid (PUFA) diet (fish oil capsules containing 3.2 g eicosapentaenoic acid and 2.2 g docohexaenoic acid)
Study: 12904324
Drug: Placebo diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo diet (olive oil capsules)
Study: 2049249
Drug: Quinine 5
Normalized name: quinine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine 5 mg kg‐1
Study: 2049249
Drug: Quinine 10
Normalized name: quinine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine 10 mg kg‐1
Study: 2049249
Drug: Quinine 15
Normalized name: quinine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine 15 mg kg‐1
Study: 6836710
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous methylprednisolone infusion
Study: 28654669
Drug: Magnesium chloride
Normalized name: Magnesium Chloride
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium chloride (248 mg of elemental magnesium per day) for 6 weeks
Study: 28654669
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment) for 6 weeks
Study: 21847611
Drug: High-low: 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-low: 3.2 g BA/day for 4 weeks, followed by 1.6 g BA/day for 4 weeks
Study: 21847611
Drug: Low-low: 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-low: 1.6 g BA/day for 8 weeks
Study: 7547157
Drug: Loperamide oxide
Normalized name: Loperamide oxide
DrugBank: Loperamide oxide (DB14661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide oxide 2 mg
Study: 7547157
Drug: Loperamide 2
Normalized name: loperamide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 2 mg
Study: 2206069
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (up to 3 gm/hr)
Study: 2206069
Drug: No tocolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No tocolytic therapy (control)
Study: 6767944
Drug: bezafibrate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate (3 x 200 mg/day)
Study: 6767944
Drug: discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: discontinuation of bezafibrate
Study: 31928611
Drug: Biological with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological with best-practice prevention (sealing-in decay, selective carious tissue removal and fissure sealants)
Study: 31928611
Drug: Best-practice prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best-practice prevention alone (dietary and toothbrushing advice, topical fluoride and fissure sealing of permanent teeth)
Study: 31928611
Drug: Biological arm
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological arm vs Conventional arm